European Pharmaceutical Review

SEPTEMBER 1, 2023

The global mRNA-based oncology therapy market is expected to reach $2 billion by 2029, according to GlobalData. BioNTech is anticipated to lead the market with a predicted $885 million in sales, and a 44.6 percent share by 2029, the research has shown. percent of the total mRNA therapy market by 2029.

Marketing 110

Marketing Sales Competition Pharmaceutical 110

European Pharmaceutical Review

JULY 19, 2024

Nathalie Moll, Director General, the European Federation of Pharmaceutical Industries and Associations (EFPIA), has commended inclusion of a “dedicated life sciences strategy” in the Political Guidelines for the Next European Commission 2024-2029. As such, she noted that the initial priority will be “prosperity and competitiveness.”

Competition 52

Competition Medicine Pharmaceutical Manufacturing 52

European Pharmaceutical Review

AUGUST 21, 2023

For 20 of the leading biopharmaceutical companies, the second quarter (Q2) of 2023 has brought an aggregate market capitalisation growth of 2.3 billion sales globally by 2029, this could offset Keytruda’s decline sales expected after its loss of exclusivity in 2028, GlobalData highlighted. trillion in the Q1 of 2023 to $3.56

Biopharma 98

Biopharma Marketing Sales Medicine 98

Medico Reach

OCTOBER 17, 2022

However, this can lead to several issues, such as: Implantation resistance due to reactionary metabolism Allergic reactions to the nickel component found in stainless steel composites Widespread bone destruction due to immunological responses to cobalt particles. billion by 2029. The US-based Enovis is leading this new development.

Medical 98

Medical Food and Drug Administration Healthcare Healthcare 98

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Marketing 52

Marketing Physicians Leads Sales 52

Pharmaceutical Technology

MAY 16, 2023

million by 2029. Although Sanofi may face generic drug competition this year for its multiple sclerosis drug, Aubagio, the company is expected to maintain their sales of Dupixent, accounting for 43.3% Johnson & Johnson maintained its leading position despite a decline of 12.8%

Marketing 52

Marketing Sales Pharma Leads 52

Quantified

SEPTEMBER 21, 2023

through 2029. Competitive pressure will drive companies to invest in AI tools for sales. Use Cases for AI Tools for Sales The sales cycle is often divided into seven stages, from lead generation to completing a sale. Once a list is compiled, the qualification process begins to determine which of the leads are possible prospects.

Sales 52

Sales Prospecting Training Sales tools 52